Learn more about whether Recursion Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

With more than 15 years of experience crafting content about all aspects of personal finance, Michael Benninger knows how to identify smart moves for your money. His work has been published by Intuit, ...

Editor's Note: APYs listed in this article are up-to-date as of the time of publication. They may fluctuate (up or down) as the Fed rate changes. CNBC Select will update as changes are made public.

The Openbank Savings account is an online high-yield savings option that has no monthly fees. You can access banking features, including checking your balance and initiating online transfers, via the ...

With close to a decade of writing and editing experience, Maisha specializes in service journalism and has produced work in the lifestyle, financial services, real estate, and culture spaces. She uses ...

Editor's Note: APYs listed in this article are up-to-date as of the time of publication. They may fluctuate (up or down) as the Fed rate changes. CNBC Select will update as changes are made public.

Stagflationary feel to U.K. data after upward surprise to inflation 30-year gilt yield hits highest since May as U.K. watchdog issues latest debt forecast by Steve Goldstein ...

Bloomberg offers a global suite of fixed income benchmarks and custom indexing capabilities. Our family of fixed income indices traces its history to the first bond ETF which was benchmarked to what ...

Yield Curve - IT News From Dow Jones Lagarde brushes off questions about France, says ECB bond-buying tool wasn't discussed at policy meeting Sep. 11, 2025 at 10:30 a.m. ET by William Watts ...